Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ICX-101
i
Other names:
ICX-101
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Incurix
Drug class:
MYC inhibitor
Related drugs:
‹
GT19077 (14)
omacetaxine mepesuccinate (4)
WB100 (3)
PLX51107 (2)
RRx-001 (2)
10058-F4 (1)
MYCi975 (1)
OMO-103 (1)
APTO-253 (0)
IDP-121 (0)
LMP744 (0)
MRX34 (0)
OTX-2002 (0)
GT19077 (14)
omacetaxine mepesuccinate (4)
WB100 (3)
PLX51107 (2)
RRx-001 (2)
10058-F4 (1)
MYCi975 (1)
OMO-103 (1)
APTO-253 (0)
IDP-121 (0)
LMP744 (0)
MRX34 (0)
OTX-2002 (0)
›
Associations
(1)
News
Trials
Filter by
Latest
over1year
ICX-101, a novel MYC inhibitor, shows antitumor activity in patient-derived cells of advanced lung cancer with high MYC expression (AACR 2023)
ICX-101 is a potent MYC inhibitor that shows antitumor activity in lung cancer PDCs. Our results suggest the potential of ICX-101 as a possible therapeutic option in advanced lung cancer with high MYC expressions.
over 1 year ago
Clinical • Metastases
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog)
|
MYC expression
|
ICX-101
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login